Although targeted EGFR therapies such as TKIs have shown substantial efficacy in the treatment of EGFR-mutant NSCLC, the emergence of TKI resistance in patients remains a significant obstacle [45]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.